Income Statement Presentation 2023

Removing allocations of Group Functions Increase in Divisional Margins of 4-5 % points, no change in Group Margins CHFM As 30 June 2022 Group Functions As published shift Restated published 31 December 2022 Group Functions shift Restated Core Operating Profit Roche Group 12,668 12,668 22,173 22,173 Pharmaceuticals Division 10,318 971 11,289 19,172 1,959 21,131 Diagnostics Division 2,560 393 2,953 3,556 825 Corporate (210) (1,574) (555) 4,381 (3,339) Core Operating Profit as % of Sales 3rd Roche Group 39.2% 39.2% 35.0% 35.0% Pharmaceuticals Division 46.2% 50.5% 42.1% 46.4% Diagnostics Division 25.7% 29.7% 20.1% 24.7% Roche 73

View entire presentation